Merck Serono

Merck Serono is a division of the global pharmaceutical and chemical group Merck KGaA, based in Darmstadt, Germany. It specializes in innovative prescription drugs, used to treat cancer, multiple sclerosis, infertility, endocrine and metabolic disorders, as well as cardiovascular diseases.

History

Merck Serono was established in 2007 following the acquisition of Swiss biotechnology company Serono by Merck KGaA. The merger combined Merck's strong capabilities in chemicals and pharmaceuticals with Serono's expertise in biotechnology.

Products

Merck Serono's product portfolio includes drugs for the treatment of cancer, multiple sclerosis, infertility, endocrine disorders, and metabolic disorders. Some of its well-known products include Rebif, a drug for the treatment of multiple sclerosis, and Erbitux, a monoclonal antibody used in cancer therapy.

Research and Development

Merck Serono is committed to discovering and developing innovative therapies that can improve patient health and quality of life. The company's research and development activities focus on a wide range of therapeutic areas, including oncology, neurology, immunology, and endocrinology.

Global Presence

Merck Serono operates in more than 150 countries around the world. Its global headquarters are located in Darmstadt, Germany, with major research and development centers in Switzerland, the United States, and Germany.

See Also

• Merck KGaA
• Pharmaceutical industry in Germany
• List of pharmaceutical companies